Rebranded Revolo Biotherapeutics showcases its plans
Revolo Biotherapeutics, which today rebranded itself from Immune Regulation, has outlined its mission to dramatically alter the autoimmune and allergic disease treatment landscape and the culmination of significant changes made over the past year, including:
- Hiring new executives internationally at every level, including CEO Jonathan Rigby;
- Building a significant presence in the USA including a new headquarters in New Orleans;
- Closing a $53.4 million Series B financing and
- Planning for the initiation of four Phase II clinical trials in the USA and Europe in 2021.
The new brand better reflects the company’s revolutionary approach to developing therapies that reset the immune system with the goal of achieving superior long-term disease remission for patients with autoimmune and allergic diseases. Revolo Bio’s drug candidates, ‘1805 and ‘1104, have already demonstrated efficacy and safety in both pre-clinical and human studies while preventing the unwanted effects of chronic immune suppression.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze